Loading...
Carmell Therapeutics Corporation
CTCXW•NASDAQ
HealthcareBiotechnology
$0.03
$-0.02(-45.40%)
Carmell Therapeutics Corporation (CTCXW) Company Profile & Overview
Explore Carmell Therapeutics Corporation’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.
Carmell Therapeutics Corporation (CTCXW) Company Profile & Overview
Carmell Therapeutics Corporation focuses on the development of plasma-based bioactive material (PBM) to stimulate tissue repair or growth after injury, disease, and aging. Its lead product candidate is CT-101 bone healing accelerant for tibia fracture healing, foot/ankle fusion, spinal fusion, dental bone graft substitute, and bone void filler; and tissue healing accelerant for androgenetic alopecia and chronic wound healing. The company was founded in 2008 and is based in Pittsburgh, Pennsylvania.
SectorHealthcare
IndustryBiotechnology
CEOMr. Rajiv Sarman Shukla
Contact Information
Company Facts
9 Employees
CountryUS